HLA-matched VSTs

Phase 1Biologic

BBaylor College of Medicine

HLA-matched VSTs is one of 4 biologic programs targeting Infections. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfectionsRecruiting

InfectionsPhase 1

Recruiting

Competition

Competitive Landscape

6 competitors in Infections

#DrugCompanyPhaseTrials

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

2 2

Temocillin

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 3

Pentaglobin

MMedical University of Vienna

Phase 2

1 4

HLA-matched VSTs

BBaylor College of Medicine

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 1Recruiting

Infections

NCT04013802

Clinical

Trials by Indication[1]

Infections1 trial

TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.

Recruiting·—·Phase 1·NCT04013802·47 enrolled

Epstein-Barr virus infection1 trial

Expanded Access Use of Multivirus-Specific Cytotoxic T-Lymphocytes for Pediatric Patients With EBV, CMV, Adenovirus, or BK Virus Infections Post Allogeneic Stem Cell Transplant

Available·BBaylor College of Medicine··NCT07104591

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for HLA-matched VSTs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HLA-matched VSTs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HLA-matched VSTs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Baylor College of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: BBaylor College of Medicine

HLA-matched VSTs

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Infections1 trial

Epstein-Barr virus infection1 trial

References

Drug Info

Quick Facts

Related News